Quest Partners LLC Purchases 12,734 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Quest Partners LLC boosted its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 181.6% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 19,748 shares of the company’s stock after buying an additional 12,734 shares during the quarter. Quest Partners LLC’s holdings in Intellia Therapeutics were worth $406,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Blue Trust Inc. raised its stake in shares of Intellia Therapeutics by 1,664.3% during the second quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock valued at $33,000 after acquiring an additional 1,398 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in Intellia Therapeutics by 763.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock worth $39,000 after buying an additional 1,550 shares during the period. Eastern Bank bought a new stake in shares of Intellia Therapeutics in the 3rd quarter worth approximately $41,000. Values First Advisors Inc. purchased a new position in shares of Intellia Therapeutics during the third quarter valued at approximately $54,000. Finally, First Horizon Advisors Inc. raised its holdings in shares of Intellia Therapeutics by 22.1% during the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock valued at $58,000 after acquiring an additional 472 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on NTLA. Royal Bank of Canada reissued an “outperform” rating and set a $54.00 price objective on shares of Intellia Therapeutics in a research report on Thursday, September 19th. Canaccord Genuity Group reiterated a “buy” rating and set a $90.00 price target on shares of Intellia Therapeutics in a research report on Tuesday, November 19th. Wedbush restated a “neutral” rating and issued a $14.00 price objective on shares of Intellia Therapeutics in a report on Monday, November 18th. Barclays reduced their target price on Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a report on Friday, November 8th. Finally, Chardan Capital raised their target price on Intellia Therapeutics from $88.00 to $91.00 and gave the company a “buy” rating in a research note on Monday, November 18th. One analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $54.94.

Intellia Therapeutics Stock Up 3.6 %

Shares of NASDAQ NTLA opened at $14.30 on Monday. The firm has a market cap of $1.46 billion, a P/E ratio of -2.63 and a beta of 1.81. Intellia Therapeutics, Inc. has a twelve month low of $12.82 and a twelve month high of $34.87. The company has a 50 day moving average of $17.97 and a 200 day moving average of $21.71.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.03. The business had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.28 million. During the same period in the previous year, the company earned ($1.38) earnings per share. The company’s revenue for the quarter was down 24.1% compared to the same quarter last year. As a group, equities analysts expect that Intellia Therapeutics, Inc. will post -5.13 earnings per share for the current fiscal year.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of the business’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the sale, the chief accounting officer now directly owns 47,012 shares in the company, valued at approximately $893,698.12. The trade was a 4.10 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 3.20% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.